Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile
MWN-AI** Summary
Celldex Therapeutics (NASDAQ:CLDX), based in Hampton, New Jersey, has announced several significant presentations at the upcoming 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, scheduled for February 27 to March 2 in Philadelphia. These presentations will focus on the company’s promising investigational therapy, barzolvolimab, which is currently being evaluated in Phase 2 clinical trials for chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD).
Key discussions include new findings from the Open Label Extension (OLE) of the Phase 2 ColdU and SD study, revealing that retreatment with barzolvolimab rapidly restores urticaria control following symptom recurrence. Specific presentations will feature barzolvolimab’s ability to enhance quality of life for patients with chronic inducible urticaria and demonstrate its prolonged efficacy even after treatment cessation.
Celldex emphasizes barzolvolimab's unique approach as a humanized monoclonal antibody that inhibits the KIT receptor on mast cells, addressing crucial mechanisms in allergic responses and inflammatory diseases like chronic urticaria. The company believes that these attributes position barzolvolimab as a first-in-class therapy and potentially a "best-in-disease" treatment for patients suffering from these allergic conditions.
With ongoing Phase 3 studies for both CSU and ColdU/SD and exploratory studies in related indications like prurigo nodularis and atopic dermatitis, Celldex is at the forefront of developing innovative, antibody-based therapies in immunology. The presentations aim to highlight the substantial clinical benefits of barzolvolimab and reinforce Celldex's commitment to improving patient outcomes in allergic and autoimmune disorders.
All presentation materials will be available on the Celldex website following the conference.
MWN-AI** Analysis
Celldex Therapeutics (NASDAQ: CLDX) is positioning itself strongly within the biotech sector, particularly with its latest announcements surrounding barzolvolimab, an innovative humanized monoclonal antibody targeting mast cells for conditions like chronic spontaneous urticaria (CSU) and cold urticaria (ColdU). The upcoming presentations at the AAAAI 2026 conference underscore the promising results from Phase 2 trials and the drug’s potential to reshape treatment protocols for allergic skin diseases.
The data to be presented—highlighting rapid improvement in symptoms upon retreatment—could reinforce barzolvolimab's position as a first-in-class therapy and a “best-in-disease” option for patients with chronic inducible urticaria. As these presentations will be held during a high-profile Allergy and Immunology conference, they may attract significant attention from the medical community, investors, and analysts alike. This can translate into increased institutional interest and potential catalyst-driven momentum in the stock price.
Investors should monitor the market reaction to the new data closely. If the results resonate positively, we could see an uptick in share value, particularly ahead of the Phase 3 studies, for which later-stage data is pivotal in attracting further investment and support from key stakeholders. While the forward-looking statements highlight inherent risks—ranging from clinical trial uncertainties to regulatory hurdles—the potential for commercializing a unique treatment option is considerable.
In light of the recent developments and upcoming presentations, investors may consider strategically accumulating shares as sentiment shifts could precede positive news. However, vigilance is advised, given the biotechnology sector's inherent volatility; staying informed of clinical progress and market trends for Celldex remains crucial for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD) have been accepted for presentation at the 2026 American Academy of Allergy, Asthma & Immunology's (AAAAI) Annual Meeting being held in Philadelphia, February 27 – March 2.
New data from the Phase 2 ColdU and SD Open Label Extension (OLE) will be presented as a late breaker, highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after symptom recurrence.
All presentations will be posted on the Celldex website at the dates/times listed below. Presentation details are as follows:
Trial: Phase 2 ColdU and SD Study
Presentation: Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria
Session Date / Time: 2/27/2026, 2:45 pm - 3:45 pm
Title: Allergic Skin Diseases
Type: Poster Session
Poster Number: 072
Location: Convention Center, Level 2, Hall E
Trial: Phase 2 CSU Study
Presentation: Prolonged Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria
Session Date / Time: 2/27/2026, 2:45 pm - 3:45 pm
Title: Allergic Skin Diseases
Type: Poster Session
Poster Number: 075
Location: Convention Center, Level 2, Hall E
Trial: Phase 2 ColdU and SD Study
Presentation: Retreatment with Barzolvolimab Leads to Rapid Improvement in Urticaria Control After Symptom Recurrence in Chronic Inducible Urticaria
Session Date / Time: 3/1/2026, 9:45 am - 10:45 am
Title: Late Breaking Poster Session II
Type: Poster Session LB
Poster Number: L41
Location: Convention Center, Level 2, Hall E
About Barzolvolimab
Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that targets mast cells by binding with high specificity to a unique part of the KIT receptor and potently inhibiting its activity. The KIT receptor is abundantly expressed by mast cells and critical for their function and survival. Mast cells are drivers of inflammatory responses such as hypersensitivity and allergic reactions and, in certain inflammatory diseases, such as chronic urticarias, mast cell activation plays a central role in the onset and progression of the disease. Based on data from robust, randomized, placebo controlled Phase 2 studies, barzolvolimab has significant potential as a first in class and best in disease treatment option for patients with chronic spontaneous urticaria (CSU), cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is currently being studied in Phase 3 studies in CSU and ColdU/SD and Phase 2 studies in prurigo nodularis (PN) and atopic dermatitis (AD), with additional indications planned for the future.
About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
Visit www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159) and CDX-622, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
FAQ**
How does Celldex Therapeutics Inc. CLDX plan to address the risks and uncertainties associated with the ongoing Phase 3 clinical trials for barzolvolimab in chronic spontaneous urticaria and other indications?
What specific milestones does Celldex Therapeutics Inc. CLDX aim to achieve in the upcoming presentations at the AAAAI Annual Meeting regarding barzolvolimab's efficacy in urticaria treatment?
Can Celldex Therapeutics Inc. CLDX provide insights on how the new data from the Phase 2 studies might influence investor confidence in their future clinical developments?
How does Celldex Therapeutics Inc. CLDX intend to secure the necessary capital for the continued development of barzolvolimab and other projects in their pipeline?
**MWN-AI FAQ is based on asking OpenAI questions about Celldex Therapeutics Inc. (NASDAQ: CLDX).
NASDAQ: CLDX
CLDX Trading
-1.04% G/L:
$28.91 Last:
319,288 Volume:
$28.81 Open:
